Boulder life-sciences leaders: Pfizer's exit means opportuni

The Boulder Valley's economic outlook may have taken a punch to the gut this month when biopharmaceutical giant Pfizer announced that it plans to shutter its research and development operations in Boulder by the middle of this year, eliminating an enterprise that at one point employed nearly 300 people at its Walnut Street facility.

Related Keywords

Chicago , Illinois , United States , Denver , Colorado , Front Range , California , Boulder , Colorado State University , Boston , Massachusetts , Jennie Smoly Caruthers , Becky Potts , Aaron Spear , Jeremy Wilson , Kyle Lefkoff , Chris Malme , Marvin Caruthers , Annsley Dylla , Scott Hutton , Amy Beckley , Elyse Blazevich , Trey Foskett , Joey Azofeifa , Berg Hill Greenleaf Ruscitti , David Kerr , Brynmor Rees , Troy Parker , Plante Moran , Joseph Hovancak , Archerdx Inc , University Of Colorado Boulder , Boulder Economic Council , Neva Analytics , Pfizer , Kohl Department , Dean Callan Co , Agilent Technologies , Biofrontiers Institute , Boulder Chamber , Boulder Ventures Ltd , Colorado Bioscience Association , Invitae Corp , Biodesix Inc , Boulder Valley , Walnut Street , Colorado Boulder , Array Biopharma , Timothy Joy , Jennie Smoly Caruthers Biotechnology Building , Colorado Bioscience , Bay Area , Venture Partners , Beau Gamble , Dean Callan , Arpeggio Biosciences ,